Market News & Trends
Hemispherx Biopharma Announces Major Breakthrough
Hemispherx Biopharma, Inc. recently announced it has received approval of its New Drug Application (NDA) from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)…
BioTelemetry Agrees to License Proprietary Technology to Bloom Technologies
BioTelemetry, Inc. recently announced it has entered into a strategic partnership with Bloom Technologies, Inc. Under the terms of the agreement, Bloomlife will pay BioTelemetry…
BioPharmX Enrolls First Subject in OPAL Phase IIb Clinical Trial
BioPharmX Corporation recently announced that the first subject has been enrolled in its Phase IIb clinical trial assessing the efficacy and safety of BPX-01 for…
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9…
Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica (the Company) announces a new research collaboration with UCL (University College London) which will see the Company utilize UCL’s novel T cell receptor (TCR)…
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9…
Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica (the Company) announces a new research collaboration with UCL (University College London) which will see the Company utilize UCL’s novel T cell receptor (TCR)…
Female Health Company & Aspen Park Pharmaceuticals Announce FDA Clears Pathway
The Female Health Company (FHC) and Aspen Park Pharmaceuticals, Inc. (APP) recently announced that the US FDA has agreed to an expedited regulatory pathway for…
Phillips-Medsize to be Acquired by Molex
Phillips-Medisize Corporation recently announced it has entered into a binding agreement to be acquired by Molex LLC, a global manufacturer of complete interconnect solutions. Phillips-Medisize…
Portola Pharmaceuticals Receives Complete Response Letter From FDA
Portola Pharmaceuticals Inc. recently announced it has received a Complete Response Letter (CRL) from the US FDA regarding its Biologics License Application (BLA) for AndexXa…
Piramal Enterprises Enters Agreement to acquire Ash Stevens
Piramal Enterprises Limited recently announced that its wholly owned subsidiary in the US has entered into an agreement to acquire 100% stake in Ash Stevens…
Crown Bioscience Center of Excellence Expands Services
Crown Bioscience has expanded its oncology services with new models, cell lines, and assays at its Center of Excellence for Oncology in San Diego. The…
Audentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Study
Audentes Therapeutics, Inc. recently announced that the first patient has been enrolled in INCEPTUS, a prospective study designed to characterize the disease presentation in children…
ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
Dahanu, India 19th August, 2016 ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received…
ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
Dahanu, India 19th August, 2016 ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received…
Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably…
Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably…
Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound…
Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound…
Scientists Find Important Clue to Restoring Muscle Function
ChromaDex Corp. recently announced that University of Pennsylvania researchers have uncovered an important clue as to why our muscles weaken as we age, and how…
